Cassava Sciences (SAVA) Stock Analysis

What Cassava Sciences does

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

Key metrics

ETFs linked to SAVA

Broad-market and Healthcare sector ETFs an investor holding Cassava Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SAVA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cassava Sciences?

Cassava Sciences trades under the ticker SAVA on NASDAQ.

Which exchange is SAVA listed on?

SAVA is listed on NASDAQ.

What sector does Cassava Sciences operate in?

Cassava Sciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SAVA in a portfolio?

PortView shows SAVA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.